Johnson & Johnson Cash Flow Conversion Efficiency
Johnson & Johnson cash flow conversion efficiency. Based on the latest financial reports, Johnson & Johnson (JNJ) has a cash flow conversion efficiency ratio of 0.116x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($9.17 Billion) by net assets ($79.28 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Johnson & Johnson (1989–2024)
Cash flow conversion efficiency of Johnson & Johnson from 1989 to 2024. This chart illustrates how Johnson & Johnson's cash flow conversion efficiency has evolved over time, based on yearly financial data. View JNJ share price today for real-time trading data and today's change.
Johnson & Johnson Cash Flow Conversion Ratio Explained
Johnson & Johnson cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Johnson & Johnson Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Johnson & Johnson ranked by their cash flow conversion efficiency. Also see market cap of Johnson & Johnson for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ASML Holding N.V.
AS:ASML
|
0.078x |
|
Exxon Mobil Corp
NYSE:XOM
|
0.048x |
|
SK HYNIX GDR 144A/REGS 1
F:HY9H
|
0.173x |
|
Visa Inc. Class A
NYSE:V
|
0.186x |
|
Tencent Holdings Ltd
F:NNND
|
0.054x |
|
ASML Holding NV ADR
NASDAQ:ASML
|
-0.105x |
|
SK Hynix Inc
KO:000660
|
0.143x |
|
ASML HOLDING NY EO-09
F:ASMF
|
-0.105x |
Annual Cash Flow Conversion Efficiency for Johnson & Johnson (1989–2024)
The table below shows the annual cash flow conversion efficiency of Johnson & Johnson from 1989 to 2024. Review JNJ cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $71.49 Billion | $24.27 Billion | 0.339x | +2.43% |
| 2023-12-31 | $68.77 Billion | $22.79 Billion | 0.331x | +20.09% |
| 2022-12-31 | $76.80 Billion | $21.19 Billion | 0.276x | -12.74% |
| 2021-12-31 | $74.02 Billion | $23.41 Billion | 0.316x | -14.97% |
| 2020-12-31 | $63.28 Billion | $23.54 Billion | 0.372x | -5.53% |
| 2019-12-31 | $59.47 Billion | $23.42 Billion | 0.394x | +5.97% |
| 2018-12-31 | $59.75 Billion | $22.20 Billion | 0.372x | +6.16% |
| 2017-12-31 | $60.16 Billion | $21.06 Billion | 0.350x | +31.33% |
| 2016-12-31 | $70.42 Billion | $18.77 Billion | 0.267x | -1.64% |
| 2015-12-31 | $71.15 Billion | $19.28 Billion | 0.271x | +1.21% |
| 2014-12-31 | $68.99 Billion | $18.47 Billion | 0.268x | +13.85% |
| 2013-12-31 | $74.05 Billion | $17.41 Billion | 0.235x | -0.99% |
| 2012-12-31 | $64.83 Billion | $15.40 Billion | 0.237x | -5.19% |
| 2011-12-31 | $57.08 Billion | $14.30 Billion | 0.250x | -13.50% |
| 2010-12-31 | $56.58 Billion | $16.39 Billion | 0.290x | -11.59% |
| 2009-12-31 | $50.59 Billion | $16.57 Billion | 0.328x | -6.99% |
| 2008-12-31 | $42.51 Billion | $14.97 Billion | 0.352x | +0.05% |
| 2007-12-31 | $43.32 Billion | $15.25 Billion | 0.352x | -2.86% |
| 2006-12-31 | $39.32 Billion | $14.25 Billion | 0.362x | +18.11% |
| 2005-12-31 | $38.71 Billion | $11.88 Billion | 0.307x | -12.31% |
| 2004-12-31 | $31.81 Billion | $11.13 Billion | 0.350x | -11.27% |
| 2003-12-31 | $26.87 Billion | $10.60 Billion | 0.394x | +9.47% |
| 2002-12-31 | $22.70 Billion | $8.18 Billion | 0.360x | -1.52% |
| 2001-12-31 | $24.23 Billion | $8.86 Billion | 0.366x | +13.67% |
| 2000-12-31 | $20.39 Billion | $6.56 Billion | 0.322x | -8.10% |
| 1999-12-31 | $16.21 Billion | $5.68 Billion | 0.350x | +0.88% |
| 1998-12-31 | $14.08 Billion | $4.89 Billion | 0.347x | -1.23% |
| 1997-12-31 | $12.36 Billion | $4.34 Billion | 0.351x | -2.14% |
| 1996-12-31 | $10.84 Billion | $3.89 Billion | 0.359x | -3.97% |
| 1995-12-31 | $9.04 Billion | $3.38 Billion | 0.374x | -10.49% |
| 1994-12-31 | $7.12 Billion | $2.98 Billion | 0.418x | +7.28% |
| 1993-12-31 | $5.57 Billion | $2.17 Billion | 0.389x | -5.96% |
| 1992-12-31 | $5.17 Billion | $2.14 Billion | 0.414x | +39.07% |
| 1991-12-31 | $5.63 Billion | $1.68 Billion | 0.298x | -11.96% |
| 1990-12-31 | $4.90 Billion | $1.66 Billion | 0.338x | +12.22% |
| 1989-12-31 | $4.15 Billion | $1.25 Billion | 0.301x | -- |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bow… Read more